Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
about
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytesFrom oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue culturesTyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.Cyclooxygenase-2 and its regulation in inflammation.Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.Role of oral teriflunomide in the management of multiple sclerosis.An update of teriflunomide for treatment of multiple sclerosis.Teriflunomide.Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?Leflunomide in renal transplantation.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosisLeflunomide suppresses growth in human medullary thyroid cancer cells.Teriflunomide for oral therapy in multiple sclerosis.A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.Leflunomide-associated skin ulceration.Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient.Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease.Janus kinase 3: a novel target for selective transplant immunosupression.Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma.
P2860
Q24800491-62F37111-D6E6-4FBC-BFD1-2E48F08B53E6Q30168082-BAE21193-4ABD-43D3-AAFD-179E661DAF3CQ33614540-33F2D5CE-289F-40E1-8285-1B1616EC6B9CQ34240771-007B8581-441F-4BA4-80C7-BFA988142E5BQ34389332-329C551D-26DF-4287-A140-476DBE3730CBQ34942389-8F43201E-50DB-450B-BBEA-249725B499F0Q35552648-CCF4789B-2D79-4E13-8B3B-8A4F1C1E7C60Q36181201-D6FC0193-3C37-495C-99F2-3D0C194FC38EQ36296416-5E8176F9-9364-43DC-954A-349C05A5E99FQ36628126-9788D2F5-6FC3-4FD9-8850-0581D62B2206Q36694418-9303774E-5071-44A9-B53B-1DACFC6D8517Q36803649-58D0178F-66CC-457C-BE9A-4203D1B926EFQ36906008-FB0253B6-2DBF-49C7-9603-9ECD7F068DE4Q37340103-75EDFBF7-7951-4804-9D84-EE0AC790BEE7Q37580399-50DF7834-5ADD-4A28-BA07-3EA2C7DD836DQ37637240-BF472231-D1BA-43E4-ABB9-5B729D7FF4DBQ37877256-C994826D-D4E0-4F28-A38B-A3D586DC95DEQ38117110-2E380AF4-E1E1-4648-B302-F82F8A61C648Q38216015-43905E72-411D-44A5-AA11-DFCAD2ECAC4EQ39132342-75BD161D-4017-4C18-925E-17BB58929F2EQ39504360-7FD3A0A2-32F9-4793-9D2B-76EB4D80C64EQ43194354-CC079D62-B956-4D7B-84AE-06BF7CA273E8Q44001927-E036F844-4EB8-470E-9671-25441691B1D8Q45024320-303901D4-7A41-4AD2-BFE4-9F467B2C3AF7Q45088597-57A289D9-D92E-46AC-BAC0-E1AAAA7EE405Q45140579-DF6FB781-06FE-499E-9A77-4B8EC6118F70Q45177699-22627ABE-2F5B-4A4E-AC5F-F20396E7E774Q47682285-B66A849D-C308-40F4-81FF-3A0994455A87Q54136937-E2BCF985-AFD1-4203-882A-64AB7DB08AEE
P2860
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Inhibition of the epidermal gr ...... inase activity by leflunomide.
@en
type
label
Inhibition of the epidermal gr ...... inase activity by leflunomide.
@en
prefLabel
Inhibition of the epidermal gr ...... inase activity by leflunomide.
@en
P2093
P2860
P1433
P1476
Inhibition of the epidermal gr ...... inase activity by leflunomide.
@en
P2093
P2860
P304
P356
10.1016/0014-5793(93)81704-4
P407
P577
1993-11-01T00:00:00Z